Leveraging RWD to Improve Outcomes for Patients With Mantle Cell Lymphoma
November 18, 2021
A collaboration between Janssen and Flatiron Health led to advancements in the research and care of patients with Mantle Cell Lymphoma. Using real world data (RWD), investigators assessed how different treatment approaches impacted patient outcomes.
“In this interview, researchers from Janssen, Weill Cornell Medicine and Flatiron Health discuss what went into building this dataset and considerations for using real-world data. In particular, they share the findings from a study which utilized this dataset — a recently accepted Oral Presentation at ASCO 2021.” Learn more here.
(Source: Flatiron, 2021)